Our aim is to understand the specific mechanisms that give rise to SCRD in neuropsychiatric disease. Our laboratory-based team of circadian and sleep biologists, behavioural scientists and pharmacologists will address this issue by characterising the genetic, cellular, anatomical and physiological mechanisms underlying SCRD.
By understanding how these processes correspond to those involved in neuropsychiatric disease we can begin to develop new treatments for these conditions. We are working closely with clinical researchers to ensure our findings can be translated effectively from laboratory to clinic, providing new drugs and treatments for SCRD and neuropsychiatric illness.
- Stuart Peirson, NDCN
- David Bannerman, Experimental Psychology
- Laurence Brown, NDCN
- Kay Davies, DPAG
- Russell Foster, NDCN
- Paul Harrison, Psychiatry
- Sridhar Vasudevan, Pharmacology
- Vladyslav Vyazovskiy, DPAG
V. Pilorz, S.K. Tam, S. Hughes, C.A. Pothecary, A. Jagannath, M.W. Hankins, D.M. Bannerman, S.L. Lightman, V.V. Vyazovskiy, P.M. Nolan, R.G. Foster, & S.N. Peirson (2016) PLoS Biol, 14(6)
G. Banks, P.M. Nolan, & S.N. Peirson (2016) Mamm Genome, 27(7-8)
D. Pritchett, A.M. Taylor, C. Barkus, S.J. Engles, N.J. Brandon, T. Sharp, R.G. Foster, P.J. Harrison, S.N. Perison, & D.M. Bannerman (2016) European Journal of Neuroscience.
For more archived publications click here